Since DDR is involved in cancer development and is a molecular target of cancer treatment, biomarkers of treatment response, combination strategies with other anticancer agents, resistance mechanisms, and liabilities of treatment with DDR inhibitors are also discussed. Here, DDR1 is linked to cancer.